VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Separately, Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Stock Up 9.9 %

Shares of VolitionRx stock opened at $0.60 on Monday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The company has a 50 day moving average price of $0.68 and a 200 day moving average price of $0.69. The firm has a market capitalization of $55.68 million, a P/E ratio of -1.51 and a beta of 1.10.

VolitionRx (NYSE:VNRX) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.34 million. As a group, research analysts anticipate that VolitionRx will post -0.31 earnings per share for the current fiscal year.

Insider Transactions at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes purchased 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the completion of the purchase, the director now directly owns 406,683 shares in the company, valued at $272,477.61. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC raised its position in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.